Article Information
History
- February 21, 2022.
Article Versions
- You are currently viewing Version 1 of this article (February 21, 2022 - 23:54).
- Version 2 (February 25, 2022 - 12:36).
- View Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Nagendrakumar Balasubramanian Singanallur1,†,
- Petrus Jansen van Vuren1,†,
- Alexander J McAuley1,†,
- Matthew P Bruce1,
- Michael J Kuiper2,
- StellaMay Gwini3,4,
- Shane Riddell1,
- Sarah Goldie1,
- Trevor W Drew1,
- Kim R Blasdell1,
- Mary Tachedjian1,
- Shruthi Mangalaganesh1,5,
- Simran Chahal1,
- Leon Caly6,
- Julian D Druce6,
- Jennifer A Juno7,
- Stephen J Kent7,
- Adam K Wheatley7 and
- Seshadri Vasan1,8,*
- 1Australian Centre for Disease Preparedness (ACDP), Commonwealth Scientific and Industrial Research Organisation (CSIRO) Health and Biosecurity, Geelong, VIC 3220, Australia
- 2Data61, Commonwealth Scientific and Industrial Research Organisation (CSIRO), Docklands 3008, VIC, Australia
- 3Biostatistics Support Service, Barwon Health, Geelong, VIC 3220, Australia
- 4School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC 3004, Australia
- 5Monash Biomedicine Discovery Institute, Monash University, Clayton, VIC 3168, Australia
- 6Victorian Infectious Diseases Reference Laboratory (VIDRL), The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia
- 7Department of Microbiology and Immunology, University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia
- 8Department of Health Sciences, University of York, York, YO10 5DD, United Kingdom
- ↵*Correspondence:
Prof. Seshadri S. Vasan, vasan.vasan{at}csiro.au;
↵† These authors have contributed equally to this work and share first authorship
Posted February 21, 2022.
At Least Three Doses of Leading Vaccines Essential for Neutralisation of SARS-CoV-2 Omicron Variant
